Current anti-migraine medications are only moderately effective and often not well tolerated. In addition, overuse of anti-migraine medications is an essential factor in the worsening of the disease and its development into chronic migraine. Cefaly (R) is therefore a means of choice to treat a majority of migraine patients.
Cefaly(R) is an innovative medical device protected by a number of patents. It is the first device to offer external cranial neurostimulation. Cranial neurostimulation is a technique that has been used for a number of years in neurology, but this has been carried out using implantable neurostimulators (similar to pacemakers). The technological advances made by Cefaly means that there is now a simple, lightweight, economical and comfortable device available that offers migraine patients a method of treatment that is neither drug-based nor invasive.
A self-adhesive electrode is placed on the forehead and the device is positioned on this electrode, worn like a pair of glasses. Highly precise impulses are transmitted through the electrode to the nerve endings of the upper branch of the trigeminal nerve.
The Cefaly(R) medical device is available on the European market and in Canada; FDA approval for USA is expected in the coming months.